Myelodysplastic Syndromes — Higher-Risk (IPSS-R high / very high; includes MDS-EB) · line 1 · Azacitidine (MDS-HR 1L)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | standard |
| Linked regimen | REG-AZA-MDS-HR |
| ID | IND-MDS-HR-1L-AZA |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-MDS-HR |
| Sources | SRC-ESMO-MDS-2021 SRC-IPSS-M-BERNARD-2022 SRC-NCCN-AML-2025 |
Notes
Standard track for MDS-HR 1L. Treatment intent: disease modification + alloHCT bridging in eligible patients. STUB — requires clinical co-lead signoff.
Used By
Algorithms
ALGO-MDS-HR-1L- ALGO-MDS-HR-1L